Valuation : Lundbeck

Market Cap 43.68B 6.79B 5.84B 5.5B 5.02B 9.39B 641B 9.42B 64.96B 25.21B 329B 25.5B 24.94B 1,060B P/E 2026 *
9.72x
P/E 2027 * 9.52x
Enterprise Value 47.68B 7.41B 6.38B 6B 5.48B 10.26B 700B 10.28B 70.92B 27.52B 359B 27.84B 27.23B 1,157B EV / Sales 2026 *
1.84x
EV / Sales 2027 * 1.67x
Free-Float
30.74%
Yield 2026 *
3.52%
Yield 2027 * 3.17%
1 day-0.91%
1 week+3.83%
Current month+3.83%
1 month+22.08%
3 months+20.56%
6 months+26.72%
Current year+19.89%
1 week 41.65
Extreme 41.65
44.65
1 month 35.1
Extreme 35.1
44.65
Current year 31.4
Extreme 31.4
44.65
1 year 31.4
Extreme 31.4
44.65
3 years 23.3
Extreme 23.3
44.65
5 years 21.94
Extreme 21.935
44.65
10 years 21.94
Extreme 21.935
44.65
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-30
Director of Finance/CFO 49 2022-08-31
Chief Operating Officer 52 -
Director TitleAgeSince
Director/Board Member 67 2015-03-24
Director/Board Member 67 2015-03-24
Director/Board Member 60 2018-03-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%+3.83% - - 6.79B
-1.45%+1.63%+32.09%+120.79% 106B
-0.58%+5.38%+65.27%+183.30% 57.49B
-0.37%0.00%-11.51%+263.51% 22.39B
+1.09%+1.28%-9.33%-5.78% 8.26B
-0.33%-1.05%-37.27%-27.44% 7.15B
-1.22%+3.36%+5.72%+30.44% 6.79B
+0.89%+2.13%-15.26%-24.62% 6.24B
+0.21%0.00%-5.41%+19.23% 5.1B
+0.77%+7.57%+347.88%+496.92% 4.56B
Average -0.19%+2.29%+41.35%+117.37% 24.87B
Weighted average by Cap. -0.84%+2.58%+35.97%+140.27%

Financials

2026 *2027 *
Net sales 25.91B 4.03B 3.47B 3.26B 2.98B 5.57B 380B 5.59B 38.53B 14.95B 195B 15.12B 14.79B 629B 26.03B 4.05B 3.48B 3.28B 2.99B 5.6B 382B 5.61B 38.72B 15.02B 196B 15.2B 14.86B 632B
Net income 4.58B 712M 613M 577M 527M 985M 67.24B 988M 6.81B 2.64B 34.5B 2.67B 2.62B 111B 4.66B 724M 623M 586M 535M 1B 68.35B 1B 6.93B 2.69B 35.07B 2.72B 2.66B 113B
Net Debt 4B 622M 535M 504M 460M 861M 58.75B 863M 5.95B 2.31B 30.14B 2.34B 2.29B 97.11B -178M -27.63M -23.77M -22.37M -20.43M -38.22M -2.61B -38.33M -264M -103M -1.34B -104M -101M -4.31B
Logo Lundbeck
H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.
Employees
5,000
Date Price Change Volume
26-09-07 DKK 43.35 -1.14% 84,878
26-09-04 DKK 43.85 -0.23% 86,750
26-09-03 DKK 43.95 +0.57% 259,955
26-09-02 DKK 43.70 +2.58% 243,235
26-09-01 DKK 42.60 +1.91% 251,082
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
44.12DKK
Average target price
48.73DKK
Spread / Average Target
+10.45%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!